Glycodelin 在子宫内膜癌和子宫颈癌的表达

目的探讨免疫抑制性糖蛋白(Glycodelin)在子宫内膜癌及子宫颈癌的表达.方法采用免疫组织化学S-P法检测Glycodelin在30例子宫内膜癌及20例子宫颈癌组织中的表达,并评价其与临床病理分期和组织学分级的关系.结果Glycodelin在子宫内膜癌、子宫颈鳞癌和子宫颈腺癌的表达率分别为73%(22/30)、53.33%(8/15)和60%(3/5),3组之间无统计学差异(P>0.05).各临床病理分期的阳性率(子宫内膜癌I期75%, II期75.00%,III期50%;子宫颈癌Ia 60%,Ib 44.44%,IIa 66.66%)无统计学差异(P>0.05).各组织学分级的阳性率(子宫内膜癌G1 70%, G2 77.78%和G3 66.67%;子宫颈癌G1 59.14%, G2 50.00%和G3 60.00%)无统计学差异, P>0.05.结论Glycodelin在子宫内膜腺癌和子宫颈癌均有表达,其表达与临床病理分期和组织学分级无明显关系.

The study of Glycodelin expression in endometrial carcinoma and cervical cancer

Aim: To study the expression of immunosuppressive glycoprotein Glycodelin in endometrial carcinoma and cervical cancer. Methods: Immunohistochemical S-P assay was used to detect the expression of Glycodelin in paraffin-embedded sections of 30 cases of endometrial carcinoma and 20 cases of cervical cancer. The relationship between Glycodelin expression and clinicopathological characteristics was evaluated. Results: The positive immunostaining rate of Glycodelin in endometrial carcinoma, squamous cell carcinoma of the cervix and adenocarcinoma of the cervix was 73%(22/30), 53.33%(8/15) and 60%(3/5), respectively; there were no significant difference between each group, P>0.05. There were no significant differences between each clinicopathological stage(in endometrial carcinoma: stage I 75.00%, stage II 75.00% and stage III 50%;in cervical cancer:stage Ia 60%,stage Ib 44.44% and stage IIa 66.66%),P>0.05. No significant differences between each histological grade were found (in endometrial carcinoma: G_1 70%, G_2 77.78% and G_3 66.67%;in cervical cancer:G_1 59.14%,G_2 50.00% and G_3 60.00%),P>0.05. Conclusion:Glycodelin is expressed in endometrial carcinoma and cervical cancer,its expression is not correlated with clinicopathological staging or histological grade.